利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

87 条记录 (耗时 0.02 秒)

    Tripeptides and methods
    6.
    发明授权
    Tripeptides and methods 失效
    三肽和方法

    公开(公告)号：US4215112A

    公开(公告)日：1980-07-29

    申请号：US20159

    申请日：1979-03-14

    申请人： Gideon Goldstein ,  George Heavner

    发明人： Gideon Goldstein ,  George Heavner

    IPC分类号： C07K5/08 ,  A61K38/22 ,  A61P37/04 ,  A61P43/00 ,  C07C237/12 ,  C07C237/22 ,  C07K5/02 ,  C07K5/09 ,  A61K37/00 ,  C07C103/52

    CPC分类号： C07K5/0815 ,  Y10S930/18

    摘要： There are disclosed new biological active polypeptides:A--X--Bwherein A is deamino-LYS or LYS; X is a suitable neutral aliphatic amino acid residue; e.g., one selected from the group consisting of SER, ALA, 2-Me-ALA, GLY, LEU, THR, D-SER, D-ALA, D-THR, allo-THR, D-LEU, and SAR; B is GLN-R', decarboxy-GLN, or ##STR1## and R' is a substituent which does not substantially affect the biological activity of the tripeptide.These polypeptides have the capability of inducing the differentiation of T-lymphocytes as measured by the acquisition of the thymic differentiation antigen Th-1, as well as B-lymphocytes as measured by the acquisition of the differentiation antigen Bu-1. The polypeptides are thus useful in thymic function and immunity areas such as in treatment for congenital absence of thymus. Also provided are therapeutic compositions and methods for use of the polypeptides.

    摘要翻译： 公开了新的生物活性多肽：A-X-B，其中A是脱氨基-LYS或LYS; X是合适的中性脂肪族氨基酸残基; 例如选自由SER，ALA，2-Me-​​ALA，GLY，LEU，THR，D-SER，D-ALA，D-THR，allo-THR，D-LEU和SAR组成的组中的一种; B是GLN-R'，脱羧-GLN或，R'是基本上不影响三肽生物活性的取代基。 如通过获得分化抗原Bu-1所测得的胸腺分化抗原Th-1以及B淋巴细胞的测定，这些多肽具有诱导T淋巴细胞分化的能力。 因此，多肽可用于胸腺功能和免疫领域，例如先天性缺乏胸腺的治疗。 还提供了用于多肽的治疗组合物和方法。

    Peptides having thymopoietin-like activity
    10.
    发明授权
    Peptides having thymopoietin-like activity 失效
    具有胸腺生成素样活性的肽

    公开(公告)号：US4397842A

    公开(公告)日：1983-08-09

    申请号：US248759

    申请日：1981-03-30

    申请人： Gideon Goldstein ,  George Heavner

    发明人： Gideon Goldstein ,  George Heavner

    IPC分类号： A61K38/00 ,  C07K14/66 ,  A61K37/00

    CPC分类号： C07K14/662 ,  A61K38/00 ,  Y10S930/18

    摘要： There are disclosed peptides having the following formula:A--X--Z--Y--Bwherein A is ##STR1## X is a suitable neutral, aliphatic or aromatic amino acid residue; e.g., one selected from the group consisting of ALA, 2-Me-ALA, GLY, LEU, ILE, LYS, THR, SER, PHE, MET, D-ALA, D-LEU, D-ILE, D-LYS, D-THR, allo-THR, D-SER, D-PHE, D-MET, and SAR; Z is ##STR2## Y is GLY, SER, THR, LEU, ILE, VAL, OR SAR; B IS TYR-R', D-TYR-R', decarboxy-TYR, or ##STR3## m is 3 or 4; n is 1, 2, or 3; R''' is hydrogen, C.sub.1 -C.sub.7 alkyl, C.sub.6 -C.sub.12 aryl, or C.sub.1 -C.sub.7 alkanoyl; and R and R' are substituents which do not substantially affect the biological activity of the peptides, provided that R-ARG-LYS-ASP-VAL-TYR-R' is excluded. These peptides have the capability of inducing the differentiation of T-lymphocytes but not of complement receptor (CR.sup.+) B-lymphocytes and thus are useful in a number of therapeutic areas. Also provided are derivatives of the peptides, therapeutic compositions, and methods for use of the compositions.

    摘要翻译： 公开了具有下式的肽：A-X-Z-Y-B其中A是合适的中性，脂族或芳族氨基酸残基; 例如选自ALA，2-Me-​​ALA，GLY，LEU，ILE，LYS，THR，SER，PHE，MET，D-ALA，D-LEU，D-ILE，D-LYS，D -THR，allo-THR，D-SER，D-PHE，D-MET和SAR; Z是 Y是GLY，SER，THR，LEU，ILE，VAL或OR SAR; B是TYR-R'，D-TYR-R'，脱羧-TYR或者 m是3或4; n为1,2或3; R“是氢，C 1 -C 7烷基，C 6 -C 12芳基或C 1 -C 7烷酰基; 并且R和R'是不排除基本上影响肽的生物学活性的取代基，条件是R-ARG-LYS-ASP-VAL-TYR-R'。 这些肽具有诱导T淋巴细胞分化而不是补体受体（CR +）B淋巴细胞分化的能力，因此可用于许多治疗领域。 还提供了肽的衍生物，治疗组合物和组合物的使用方法。